MDM2 and acute myeloid leukemia: With respect to the magnitude of increase in MDM2 levels after treatment with MDM2 inhibitors, AML patients treated with RG7112 exhibited a 2.8-fold increase in median MDM2 gene expression levels in peripheral blasts after 10 days of treatment.